Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC, commonly known as Hikma, is a leading global pharmaceutical company headquartered in the United Kingdom. Founded in 1978, Hikma has established a strong presence in key operational regions, including the Middle East, North Africa, and the United States. The company operates primarily in the generic and branded pharmaceuticals sectors, focusing on injectable medications, oral solids, and complex generics. Hikma is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to various therapeutic areas, including oncology, pain management, and infectious diseases. With a robust market position, Hikma has achieved significant milestones, including numerous FDA approvals and a growing pipeline of new therapies. The company's dedication to improving patient outcomes and expanding access to essential medicines underscores its reputation as a trusted leader in the pharmaceutical industry.
DitchCarbon Score
How does Hikma Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hikma Pharmaceuticals's score of 35 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hikma Pharmaceuticals's reported carbon emissions
In 2023, Hikma Pharmaceuticals reported total carbon emissions of approximately 123,638,000 kg CO2e, comprising 43,830,000 kg CO2e from Scope 1 and 79,897,000 kg CO2e from Scope 2 emissions. The company also disclosed significant Scope 3 emissions, amounting to about 925,152,000 kg CO2e, which includes emissions from capital goods, business travel, and purchased goods and services. Hikma has not set specific reduction targets or initiatives as part of its climate commitments, indicating a potential area for future development. The absence of documented reduction targets suggests that while the company is actively measuring its emissions, it may not yet have formalised strategies for reducing its carbon footprint. Overall, Hikma Pharmaceuticals is positioned within the pharmaceutical industry, which is increasingly focusing on sustainability and carbon reduction. The company's emissions data reflects its operational impact, and the lack of reduction commitments highlights an opportunity for enhanced climate action moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2013 | 2014 | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 20,831,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 51,424,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hikma Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
